Keywords: GlaxoSmithKline, XenoPort, Horizant, Postherpetic neuralgia, PHN, USA, FDA

FDA clears GlaxoSmithKline's Horizant for PHN

Article | 08 June 2012

Print This

The US Food and Drug Administration (FDA) has approved UK Pharma giant GlaxoSmithKline’s (LSE: GSK) Horizant (gabapentin enacarbil) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in